Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer
Study Information
Alliance Study ID: A031201
NCT Study ID (ClinicalTrials.gov): NCT01949337
Alliance Committee: Genitourinary Cancer
Disease or Cancer Type: Prostate Cancer
Alliance Study Chair: Michael Morris, MD
Status: UNKNOWN
Study Description
This randomized phase III trial studies enzalutamide to see how well it works compared to enzalutamide, abiraterone, and prednisone in treating patients with castration-resistant metastatic prostate cancer. Androgens can cause the growth of prostate cancer cells. Drugs, such as enzalutamide, abiraterone acetate, and prednisone, may lessen the amount of androgens made by the body.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information